<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02763956</url>
  </required_header>
  <id_info>
    <org_study_id>GelStix-SW/ NSI-TD-003</org_study_id>
    <nct_id>NCT02763956</nct_id>
  </id_info>
  <brief_title>RCT Study of the Gelstix™ Device to Treat Chronic Discogenic Low Back Pain GelStix Study</brief_title>
  <acronym>GelStix</acronym>
  <official_title>Randomized, Double-blind, Placebo-controlled, Multicenter Efficacy Study of the Gelstix™ Device to Treat Chronic Discogenic Low Back Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ospedale Regionale di Lugano</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rijnstate Ziekenhuis, Arnhem, The Netherlands</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Paolo Maino, Sponsor-Investigator</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ospedale Regionale di Lugano</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Degenerative Disc Disease is one of the most common spinal pathologies, affecting up to 10-15&#xD;
      % of adults. The purpose of this study is to evaluate the efficacy of treatment with the&#xD;
      GelStix™ device in a patient population with discogenic pain that had no benefit from&#xD;
      conservative care.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Degenerative Disc Disease (DDD) is one of the most common spinal pathologies, affecting up to&#xD;
      10-15 % of adults. The degeneration is associated with diminished water-binding capabilities&#xD;
      of the nucleus pulpous leading to disc dehydration, volume reduction, changes in cellular&#xD;
      activity, biomechanical changes and painful symptoms. Patients are initially treated with&#xD;
      non-surgical pain-management techniques, such as anti-inflammatory medications and physical&#xD;
      therapy, but these therapies often provide only temporary relief. When non-surgical&#xD;
      intervention fails, fusion or total disc arthroplasty are often prescribed, both of which are&#xD;
      highly invasive surgeries with significant associated morbidity. Clearly, a meaningful&#xD;
      solution for the treatment gap existing between conservative care and invasive surgical&#xD;
      intervention is needed.&#xD;
&#xD;
      The purpose of this study is to evaluate the efficacy of treatment with the GelStix™ device&#xD;
      in a patient population that had no benefit from conservative care.&#xD;
&#xD;
      The primary objective of this study is to quantify the reduction in lumbar pain in a GelStix™&#xD;
      treatment group compared with a control group receiving a saline solution injection as&#xD;
      placebo.&#xD;
&#xD;
      The secondary objectives are to assess:&#xD;
&#xD;
        1. the impact of treatment with GelStix™ on disability compared with the control group&#xD;
&#xD;
        2. the impact of treatment with GelStix™ on health related quality of life compared with&#xD;
           the control group&#xD;
&#xD;
        3. the impact of treatment with GelStix™ on reliance on medication to relieve the pain&#xD;
           compared with the control group&#xD;
&#xD;
        4. the acute and long-term safety of the GelStix™ device and implant system&#xD;
&#xD;
      The total expected number of patients to be randomized is 72. Taking into account a relevant&#xD;
      difference of 1.5 between groups on the NRS, with an SD of 2, 30 patients per group (60&#xD;
      patients in total) will be required to detect a statistically significant difference with a&#xD;
      power of 80% at an alpha of 5% (two-tailed) for unpaired Student's T test. Taking into&#xD;
      account a 20% drop out rate, 72 patients are expected to be randomized for this study.&#xD;
&#xD;
      The estimated duration for the investigational plan (from start of screening of first&#xD;
      participant to end of follow-up of last participant) is 24 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Lumbar Pain intensity measured on Numeric Rating Scale</measure>
    <time_frame>at baseline and 6 months post-treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in disability measured by the Owestry Disability Index</measure>
    <time_frame>at baseline and 6 months post-treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in health related quality of life measured by EuroQualityOfLife-5 dimensions questionnaire</measure>
    <time_frame>at baseline and 6 months post-treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reliance on medication to relieve pain: type and dose of analgesics</measure>
    <time_frame>at baseline and 6 months post-treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device-related adverse events</measure>
    <time_frame>Device-related adverse events assessed up to one year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Degeneration of Lumbar Intervertebral Disc</condition>
  <arm_group>
    <arm_group_label>Gelstix</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The intradiscal insertion of the GelStix™ Nucleus Augmentation Device.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intradiscal saline solution (1 mL NaCl 0.9%) injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>GelStix™ Nucleus Augmentation Device</intervention_name>
    <description>Intradiscal Gelstix insertion</description>
    <arm_group_label>Gelstix</arm_group_label>
    <other_name>Hydrogel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intradiscal saline injection</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Saline, NaCl 0,9%</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  discogenic pain caused by one or two levels of degenerative disc disease, confirmed by&#xD;
             MRI and positive discography&#xD;
&#xD;
          -  failure to have symptoms resolved or reduced following at least 12 weeks of&#xD;
             conservative care (pain medication and/or physical therapy)&#xD;
&#xD;
          -  negative medial branches block results&#xD;
&#xD;
          -  baseline Numeric Rating Scale (NRS) pain score ≥5/10&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  radiculopathy&#xD;
&#xD;
          -  disc herniations&#xD;
&#xD;
          -  annular tear (greater than Grade 4 Modified Dallas Grading)&#xD;
&#xD;
          -  coagulopathy or oral anticoagulant therapy (except low-dose acetylsalicylic acid) in&#xD;
             conditions that do not allow for a temporary discontinuation&#xD;
&#xD;
          -  previous lumbar surgery&#xD;
&#xD;
          -  disc height less than 5 mm at the treatment level or less than 50% the original height&#xD;
&#xD;
          -  BMI (Body Mass Index (kg/m2) of ≥ 35&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eva Koetsier, MD PhD LLM</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centro Terapia del Dolore, EOC Lugano</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eva Koetsier, MD PhD LLM</last_name>
    <phone>0041918117590</phone>
    <email>eva.koetsier@eoc.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Paolo Maino, MD PhD</last_name>
    <phone>0041918117590</phone>
    <email>paolo.maino@eoc.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rijnstate Ziekenhuis</name>
      <address>
        <city>Arnhem</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Willem Kallewaard</last_name>
      <phone>0031(0)88 - 005 8888,</phone>
      <email>jkallewaard@rijnstate.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>EOC Lugano</name>
      <address>
        <city>Lugano</city>
        <state>Ticino</state>
        <zip>6962</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eva Koetsier, MD PhD LLM</last_name>
      <phone>0041918117590</phone>
      <email>eva.koetsier@eoc.ch</email>
    </contact>
    <contact_backup>
      <last_name>Paolo Maino, MD PhD</last_name>
      <phone>0041918117590</phone>
      <email>paolo.maino@eoc.ch</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Netherlands</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>April 29, 2016</study_first_submitted>
  <study_first_submitted_qc>May 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2016</study_first_posted>
  <last_update_submitted>March 24, 2021</last_update_submitted>
  <last_update_submitted_qc>March 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ospedale Regionale di Lugano</investigator_affiliation>
    <investigator_full_name>Eva Koetsier MD PhD LLM</investigator_full_name>
    <investigator_title>MD PhD LLM</investigator_title>
  </responsible_party>
  <keyword>Gelstix, Hydrogel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Back Pain</mesh_term>
    <mesh_term>Low Back Pain</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

